Non-small cell lung cancer with EGFR exon 20 insertion mutation: a systematic literature review and meta-analysis of patient outcomes

References

• Carper MB, Claudio PP. Clinical potential of gene mutations in lung cancer. Clin Transl Med. 2015;4(1):33.
   PubMedGoogle Scholar
• Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892–2911.
   PubMed Web of Science ®Google Scholar
• Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–967.
   PubMed Web of Science ®Google Scholar
• Burnett H, Emich H, Carroll C, et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. PLoS One. 2021;16(3):e0247620.
   PubMed Web of Science ®Google Scholar
• Vyse S, Huang PH. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct Target Ther. 2019;4:5.
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Lo PC, Nishino M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013;8(2):179–184.
   PubMed Web of Science ®Google Scholar
• NICE. Alogithm for systemic treatment options for advanced non-squamous NSCLC:EGFR-TK, ALK or ROS-1 positive. 2021. 2053-6178. https://www.nice.org.uk/guidance/ng122/resources.
   Google Scholar
• European Society for Medical Oncology. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Updated version 15 September 2020. 2020.
   Google Scholar
• Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V3.2022 © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. 2022; [cited 2020 Mar 17]. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
   Google Scholar
• Hanna NH, Robinson AG, Temin S, et al. Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update. J Clin Oncol. 2021;39(9):1040–1091.
   PubMed Web of Science ®Google Scholar
• Robichaux JP, Le X, Vijayan RSK, et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature. 2021;597(7878):732–737.
   PubMed Web of Science ®Google Scholar
• Yasuda H, Park E, Yun CH, et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013;5(216):216ra177.
   PubMed Web of Science ®Google Scholar
• Takeda Pharmaceuticals America Inc. EXKIVITY™ (mobocertinib) capsules, for oral use. Prescribing Information. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf.
   Google Scholar
• Janssen Pharmaceutical Companies. RYBREVANT (amivantamab-vmjw) injection, for intravenous use Prescribing Information. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761210s000lbl.pdf.
   Google Scholar
• The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. 2011.
   Google Scholar
• Centre for Reviews and Dissemination. Systematic Reviews: CRD’s guidance for undertaking reviews in health care. 2009. https://www.york.ac.uk/media/crd/Systematic_Reviews.pdf.
   Google Scholar
• Ades AE, Caldwell DM, Reken S, et al. NICE DSU Technical Support Document 7: evidence synthesis of treatment efficacy in decision making: A Reviewer’s Checklist. 2012. www.nicedsu.org.uk.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269.
   PubMed Web of Science ®Google Scholar
• McGrath S, Zhao X, Qin ZZ, et al. One-sample aggregate data meta-analysis of medians. Stat Med. 2019;38(6):969–984.
   PubMed Web of Science ®Google Scholar
• The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. Version 5.1.0; [updated March 2011, cited 2022 Jan 13]. Available from: https://handbook-5-1.cochrane.org/chapter_10/10_4_3_1_recommendations_on_testing_for_funnel_plot_asymmetry.htm.
   Google Scholar
• Miura S. P50.03 – A Real-World Cohort Study of EGFR TKIs in Patients with NSCLCwith Uncommon EGFR mutations (UpSwinG) (Abstract). IASLC: 2021 World Conference on Lung Cancer. 2021.
   Google Scholar
• Miura S, Hsia T-C, Hung J-Y, et al. 145P UpSwinG: real-world, non-interventional cohort study on TKI activity in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations. J Thoracic Oncol. 2021;16(4):S776–S777.
   Web of Science ®Google Scholar
• Ou S, Lin H, Hong J, et al. Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertionmutations. Am Soc Clin Oncol. 2021;39(15):9098–9098.
   Web of Science ®Google Scholar
• Dersarkissian M, Bhak R, Lin H, et al. P2.01-103 real-world treatment patterns and survival in non-small cell lung cancer patients with EGFR exon 20 insertion mutations. J Thoracic Oncol. 2019;14(10):S681.
   Web of Science ®Google Scholar
• Minchom AR, Girard N, Bazhenova L, et al. Amivantamab compared with real-world therapies in patients with NSCLC with EGFR Exon 20 insertion mutations who have progressed after platinum doublet chemotherapy. J Clin Oncol. 2021;39(15_suppl):9052–9052.
   Web of Science ®Google Scholar
• Choudhury NJ, Schoenfeld AJ, Flynn J, et al. Response to standard therapies and comprehensive genomic analysis for patients with lung adenocarcinoma with EGFR Exon 20 insertions. Clin Cancer Res. 2021;27(10):2920–2927.
   PubMed Web of Science ®Google Scholar
• Lo PC, Jackman DM, Butaney M, et al. Clinical behavior of lung cancers harboring EGFR Exon 20 insertions. J Thoracic Oncol. 2012;7(9)(4):S206–S207.
   Web of Science ®Google Scholar
• Hastings K, Yu HA, Wei W, et al. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. Ann Oncol. 2019;30(8):1311–1320.
   PubMed Web of Science ®Google Scholar
• Bravo Montenegro G, Vanderwalde A, Raez L, et al. P76.43 Co-occurring genomic alterations and treatment outcomes in patients with EGFR exon 20 insertion positive NSCLC. J Thoracic Oncol. 2021;16(3):S605–S606.
   Web of Science ®Google Scholar
• Beau-Faller M, Prim N, Ruppert AM, et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol. 2014;25(1):126–131.
   PubMed Web of Science ®Google Scholar
• Yang G, Li J, Xu H, et al. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: molecular heterogeneity and treatment outcome from nationwide real-world study. Lung Cancer. 2020;145:186–194.
   PubMed Web of Science ®Google Scholar
• Xu CW, Wang WX, Wang D, et al. Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study. Transl Lung Cancer Res. 2020;9(5):1853–1861.
   PubMed Web of Science ®Google Scholar
• Qin Y, Jian H, Tong X, et al. Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors. Mol Oncol. 2020;14(8):1695–1704.
   PubMed Web of Science ®Google Scholar
• Yang GJ, Li J, Xu HY, et al. Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations. Lung Cancer. 2021;152:39–48.
   PubMed Web of Science ®Google Scholar
• Wang Y, Li J, Zhou Y, et al. Tumor genomics and response to chemotherapy in advanced non-small cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations. Ann Transl Med. 2020;8(20):1297.
   PubMed Web of Science ®Google Scholar
• Zhao C, Li X, Su C, et al. P1.01-111 EGFR exon20 insertion patients treated with First-Line chemotherapy in non-small cell lung cancer. J Thoracic Oncol. 2018;13(10):S507.
   Web of Science ®Google Scholar
• Chen D, Song Z, Cheng G. Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations. Onco Targets Ther. 2016;9:4181–4186.
   PubMed Web of Science ®Google Scholar
• Udagawa H, Matsumoto S, Ohe Y, et al. OA07.03 clinical outcome of non-small cell lung cancer with EGFR/HER2 exon 20 insertions identified in the LC-SCRUM-Japan. J Thoracic Oncol. 2019;14(10):S224.
   Web of Science ®Google Scholar
• Wu JY, Yu CJ, Shih JY. Effectiveness of treatments for advanced non-small-cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations. Clin Lung Cancer. 2019;20(6):e620–e630.
   PubMed Web of Science ®Google Scholar
• Ovcaricek T, Unk M, Kern I, et al. 173PD. EGFR exon 20 insertion mutations in NSCLC: frequency and treatment outcomes with EGFR directed TKIs. J Thoracic Oncol. 2012;7(6):S7–S89.
   PubMed Web of Science ®Google Scholar
• Cardona AF, Rojas L, Zatarain-Barron ZL, CLICaP, et al. EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP). Lung Cancer. 2018;125:265–272.
   PubMed Web of Science ®Google Scholar
• Christopoulos P, Grohe C, Griesinger F, et al. Real-world study of NSCLC with EGFR exon 20 insertions. J Thoracic Oncol. 2021;16(4):S780–S781.
   Web of Science ®Google Scholar
• Udagawa H, Matsumoto S, Ohe Y, et al. Clinical outcome of non-small cell lung cancer with EGFR/HER2 exon 20 insertions identified in the LC-SCRUM-Japan (poster). presented at: 2019. World Conference on Lung Cancer 2019; Barcelona, Spain.
   Google Scholar
• Riely GJ, Neal JW, Camidge DR, et al. Activity and safety of mobocertinib (TAK-788) in previously treated Non-Small cell lung cancer with EGFR exon 20 insertion mutations from a phase I/II trial. Cancer Discov. 2021;11(7):1688–1699.
   PubMed Web of Science ®Google Scholar
• Zhou C, Ramalingam SS, Kim TM, et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial. JAMA Oncol. 2021;7(12):e214761.
   PubMed Web of Science ®Google Scholar
• Zhou C. Mobocertinibin NSCLC With EGFRExon 20 Insertions: results from EXCLAIM and platinum-pretreated patient populations (poster). IASLC: 2020 World Conference on Lung Cancer. 2020.
   Google Scholar
• Ramalingam S, Zhou C, Kim TM, et al. Mobocertinib (TAK-788) in EGFR exon 20 insertion + metastatic NSCLC: additional results from platinum-pretreated patients and EXCLAIM cohort of phase 1/2 study (poster). 2021.
   Google Scholar
• Spira A, Ramalingam S, Neal J, et al. Mobocertinib in EGFR exon 20 insertion–positive metastatic NSCLC patients with disease control on prior EGFR TKI therapy (poster). IASLC: 2021 World Conference on Lung Cancer. 2021.
   Google Scholar
• Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR Exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol. 2021;39(30):3391–3402.
   PubMed Web of Science ®Google Scholar
• Nagasaka M, Goto K, Gomez JE, et al. Amivantamab in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) (poster). IASLC: 2021 World Conference on Lung Cancer. 2021.
   Google Scholar
• Cornelissen R, Garassino MC, Le X, et al. MA11.04 updated efficacy, safety and dosing management of poziotinib in previously treated EGFR and HER2 exon 20 NSCLC patients. J Thoracic Oncol. 2021;16(3):S173–S174.
   Web of Science ®Google Scholar
• Le X, Goldman JW, Clarke JM, et al. Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients. J Clin Oncol. 2020;38(15_suppl):9514–9514.
   Web of Science ®Google Scholar
• Le X, Goldman J, Clarke J, et al. Abstract CT081: Poziotinib activity and durability of responses in previously treated EGFR exon 20 NSCLC patients – a Phase 2 study. presented at: Tumor Biology; 2020.
   Google Scholar
• Sacher A, Le X, Cornelissen R, et al. 36MO safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer. Annals of Oncology. 2021;2021:32.
   Google Scholar
• Piotrowska Z, Costa DB, Oxnard GR, et al. Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions. Ann Oncol. 2018;29(10):2092–2097.
   PubMed Web of Science ®Google Scholar
• Piotrowska Z, Smit EF, Costa D. MINI30.06 activity of AUY922 in NSCLC patients with EGFR Exon 20 insertions. J Thoracic Oncol. 2015;10(9):S261–S406.
   Web of Science ®Google Scholar
• Liu SV, Villaruz LC, Lee VHF, et al. LBA61 first analysis of RAIN-701: study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions. Annals Oncol. 2020;2020:31.
   Google Scholar
• Piotrowska Z, Yu HA, Yang CH, et al. Abstract 9077: safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20) (poster). 2021.
   Google Scholar
• Han BH, Zhou C, Wu JY, et al. Preclinical and preliminary clinical investigations of furmonertinibin NSCLC with EGFR exon 20 insertions (20ins) (poster). ESMO Congress 2021. 2021.
   Google Scholar
• Janne PA, Wang M, Paul M, et al. Phase 1 studies of DZD9008, an oral, selective EGFR/HER2 inhibitor in advanced NSCLC with EGFRExon20 insertion mutation (poster). IASLC: 2021 World Conference on Lung Cancer. 2021.
   Google Scholar
• Gao G, Wang Y, Ren S, et al. P83.03 efficacy of camrelizumab (SHR-1210) Plus apatinib in advanced NSCLC with EGFR mutation. J Thoracic Oncol. 2021;16(3):S654.
   Web of Science ®Google Scholar
• van Veggal B, van der Wekken AJ, Paats MS, et al. Interim results of a phase II single arm trial combining afatinib with cetuximab inpatients with EGFRex20ins positive NSCLC. Am Soc Clin Oncol. 2021;39:15.
   Web of Science ®Google Scholar
• Riess JW, Reckamp KL, Frankel P, et al. Erlotinib and onalespib lactate focused on EGFR exon 20 insertion Non-Small cell lung cancer (NSCLC): a California cancer consortium phase I/II trial (NCI 9878). Clin Lung Cancer. 2021;22(6):541–548.
   PubMed Web of Science ®Google Scholar
• Riess JW, Groshen SG, Reckamp KL, et al. Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC: an ETCTN California cancer consortium phase I study (abstract). American Society of Clinical Oncology. 2019. Available from: https://meetinglibrary.asco.org/record/174600/abstract
   Google Scholar
• Zwierenga F, van Veggel BAMH, Hendriks LEL, et al. High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: results from a phase 2 multicenter study, POSITION20. ESMO Congress 2021. 2021. Abstract 1214P
   Google Scholar
• Piotrowska Z, Wang Y, Sequist LV, et al. ECOG-ACRIN 5162: a phase II study of osimertinib 160 mg in NSCLC with EGFRexon 20 insertions. American Society of Clinical Oncology. 2020. https://meetinglibrary.asco.org/record/184821/abstract.
   Google Scholar
• Kim TM, Ock CY, Kim M, et al. Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: a multicenter trial of the Korean Cancer study group (LU17-19). Ann Oncol. 2019;2019:30.
   Google Scholar
• Yang JCH, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16(7):830–838.
   PubMed Web of Science ®Google Scholar
• Shih J, Yu C, Su W. Activity of BIBW 2992, an irreversible EGFR/HER1 and HER2 TKI, in lung adenocarcinoma patients harboring less common EGFR mutations: 415P. Ann Oncol. 2010;21(8):viii122–viii161.
   Google Scholar
• Yang JC, Shih J-Y, Su WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012;13(5):539–548.
   PubMed Web of Science ®Google Scholar
• Yang J, Schuler M, Yamamoto N, et al. Activity of Afatinib in uncommon epidermal growth factor receptor (Egfr) mutations in lux-lung 3, a phase III trial of Afatinib or cisplatin/pemetrexed in EGFR mutation-positive lung cancer. Abstract number 2123. Ann Oncol. 2012;23(9):IX410–IX411.
   Google Scholar
• Janning M, Suptitz J, Albers-Leischner C, et al. Treatment outcome of atypical EGFR mutations in the german national network genomic medicine lung cancer (nNGM). Ann Oncol. 2022;2022:S0923-7534(22)00361-1.
   Google Scholar
• Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy. Cancer Sci. 2016;107(9):1179–1186.
   PubMed Web of Science ®Google Scholar